BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 23534723)

  • 1. Clinicopathological significance of reduced SPARCL1 expression in human breast cancer.
    Cao F; Wang K; Zhu R; Hu YW; Fang WZ; Ding HZ
    Asian Pac J Cancer Prev; 2013; 14(1):195-200. PubMed ID: 23534723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulated SPARCL1 is associated with clinical significance in human gastric cancer.
    Li P; Qian J; Yu G; Chen Y; Liu K; Li J; Wang J
    J Surg Oncol; 2012 Jan; 105(1):31-7. PubMed ID: 22161898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secreted protein acidic and rich in cysteines-like 1 suppresses aggressiveness and predicts better survival in colorectal cancers.
    Hu H; Zhang H; Ge W; Liu X; Loera S; Chu P; Chen H; Peng J; Zhou L; Yu S; Yuan Y; Zhang S; Lai L; Yen Y; Zheng S
    Clin Cancer Res; 2012 Oct; 18(19):5438-48. PubMed ID: 22891198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylation of SPARCL1 Is Associated with Oncologic Outcome of Advanced Upper Urinary Tract Urothelial Carcinoma.
    Luo HL; Chiang PH; Huang CC; Su YL; Sung MT; Tsai EM; Lin CS; Chiang PH
    Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPARCL1 impedes trophoblast migration and invasion by down-regulating ERK phosphorylation and AP-1 production and altering EMT-related molecule expression.
    Liu X; Zhao J; Luan X; Li S; Zhai J; Liu J; Du Y
    Placenta; 2020 Jan; 89():33-41. PubMed ID: 31675488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer.
    Esposito I; Kayed H; Keleg S; Giese T; Sage EH; Schirmacher P; Friess H; Kleeff J
    Neoplasia; 2007 Jan; 9(1):8-17. PubMed ID: 17325739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SPARCL1 Is a Novel Prognostic Biomarker and Correlates with Tumor Microenvironment in Colorectal Cancer.
    Zhang HP; Wu J; Liu ZF; Gao JW; Li SY
    Biomed Res Int; 2022; 2022():1398268. PubMed ID: 35111844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying liver metastasis-related hub genes in breast cancer and characterizing
    Chen M; Zheng W; Fang L
    PeerJ; 2023; 11():e15311. PubMed ID: 37180578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SPARCL1 expression increases with preoperative radiation therapy and predicts better survival in rectal cancer patients.
    Kotti A; Holmqvist A; Albertsson M; Sun XF
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1196-202. PubMed ID: 24661672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.
    Hurley PJ; Hughes RM; Simons BW; Huang J; Miller RM; Shinder B; Haffner MC; Esopi D; Kimura Y; Jabbari J; Ross AE; Erho N; Vergara IA; Faraj SF; Davicioni E; Netto GJ; Yegnasubramanian S; An SS; Schaeffer EM
    Cancer Res; 2015 Oct; 75(20):4322-34. PubMed ID: 26294211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SPARCL1 exhibits different expressions in left- and right-sided colon cancer and is downregulated via DNA methylation.
    Hu H; Wu D; Liu X; Yu H; Xu J; Cai W; Huang Y; Bai R; Zhang J; Gu Y; Zheng S; Ge W
    Epigenomics; 2021 Aug; 13(16):1269-1282. PubMed ID: 34435512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SPARCL1 a novel player in cancer biology.
    Gagliardi F; Narayanan A; Mortini P
    Crit Rev Oncol Hematol; 2017 Jan; 109():63-68. PubMed ID: 28010899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPARCL1 suppresses cell migration and invasion in renal cell carcinoma.
    Ye H; Wang WG; Cao J; Hu XC
    Mol Med Rep; 2017 Nov; 16(5):7784-7790. PubMed ID: 28944877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic organization and chromosomal mapping of SPARC-like 1, a gene down regulated in cancers.
    Isler SG; Schenk S; Bendik I; Schraml P; Novotna H; Moch H; Sauter G; Ludwig CU
    Int J Oncol; 2001 Mar; 18(3):521-6. PubMed ID: 11179481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated analysis reveals down-regulation of SPARCL1 is correlated with cervical cancer development and progression.
    Wu DM; Shi J; Liu T; Deng SH; Han R; Xu Y
    Cancer Biomark; 2018 Feb; 21(2):355-365. PubMed ID: 29103025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SPARCL1, a Novel Prognostic Predictive Factor for GI Malignancies: a Meta-Analysis.
    Hu H; Cai W; Zheng S; Ge W
    Cell Physiol Biochem; 2017; 44(4):1485-1496. PubMed ID: 29190626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SPARCL1 is a novel predictor of tumor recurrence and survival in hilar cholangiocarcinoma.
    Yu Y; Chen Y; Ma J; Yu X; Yu G; Li Z
    Tumour Biol; 2016 Mar; 37(3):4159-67. PubMed ID: 26490986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Species-, organ- and cell-type-dependent expression of SPARCL1 in human and mouse tissues.
    Klingler A; Regensburger D; Tenkerian C; Britzen-Laurent N; Hartmann A; Stürzl M; Naschberger E
    PLoS One; 2020; 15(5):e0233422. PubMed ID: 32437418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome.
    Hurley PJ; Marchionni L; Simons BW; Ross AE; Peskoe SB; Miller RM; Erho N; Vergara IA; Ghadessi M; Huang Z; Gurel B; Park BH; Davicioni E; Jenkins RB; Platz EA; Berman DM; Schaeffer EM
    Proc Natl Acad Sci U S A; 2012 Sep; 109(37):14977-82. PubMed ID: 22927397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of CacyBP is associated with poor prognosis and the effects on COX-2 expression in breast cancer.
    Nie F; Yu XL; Wang XG; Tang YF; Wang LL; Ma L
    Int J Oncol; 2010 Nov; 37(5):1261-9. PubMed ID: 20878073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.